PRAX Stock Price, Praxis Precision Medicines Quote, Chart

Market Summary

USD44.72-0.49

Delayedas of 17 May 2024, 02:06 pm

-1.08%

PRAX Stock Price

View Fullscreen

PRAX RSI Chart

PRAX Valuation

Market Cap

773.4M

Price/Earnings (Trailing)

-6.17

Price/Sales (Trailing)

352.37

EV/EBITDA

-3.37

Price/Free Cashflow

-7.8

PRAX Price/Sales (Trailing)

PRAX Profitability

EBT Margin

-8365.97%

Return on Equity

-54.61%

Return on Assets

-50.09%

Free Cashflow Yield

-12.83%

PRAX Fundamentals

PRAX Revenue

Revenue (TTM)

2.2M

Rev. Growth (Yr)

-36.9%

Rev. Growth (Qtr)

-16.31%

PRAX Earnings

Earnings (TTM)

-125.4M

Earnings Growth (Yr)

-5.73%

Earnings Growth (Qtr)

-47.33%

Breaking Down PRAX Revenue

52 Week Range

0.8347.03

(Low)(High)

Last 7 days

-9.9%

Last 30 days

-13.9%

Last 90 days

7.9%

Trailing 12 Months

4157.6%

How does PRAX drawdown profile look like?

PRAX Financial Health

Current Ratio

11.27

PRAX Investor Care

Buy Backs (1Y)

72.45%

Diluted EPS (TTM)

-20.95

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.2M	0	0	0
2023	1.3M	1.7M	2.1M	2.4M
2022	442.5K	614.0K	785.5K	957.0K
2021	205.5K	0	0	271.0K
2020	166.5K	0	0	140.0K
2019	0	0	0	193.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Praxis Precision Medicines Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 12, 2024	nemiroff alex	sold (taxes)	-2,277	44.65	-51.00	general counsel and secretary
Feb 12, 2024	mastrocola lauren	sold (taxes)	-2,143	44.65	-48.00	principal accounting officer
Feb 12, 2024	souza marcio	sold (taxes)	-12,100	44.65	-271	chief executive officer
Jan 07, 2024	kelly timothy edwin	sold (taxes)	-3,501	25.19	-139	chief financial officer
Jan 07, 2024	nemiroff alex	sold (taxes)	-2,241	25.19	-89.00	general counsel and secretary
Jan 07, 2024	mastrocola lauren	sold (taxes)	-881	25.19	-35.00	principal accounting officer
Jan 07, 2024	souza marcio	sold (taxes)	-10,529	25.19	-418	chief executive officer
Oct 05, 2023	desimone jill	bought	25,375	1.75	14,500	-
Jun 27, 2023	souza marcio	bought	10,587	1.0587	10,000	chief executive officer
May 12, 2023	nemiroff alex	acquired	10,330	0.884	11,686	general counsel and secretary

Which funds bought or sold PRAX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	PERCEPTIVE ADVISORS LLC	new	-	50,133,400	50,133,400	0.87%
May 15, 2024	MARSHALL WACE, LLP	added	147	6,296,680	7,384,880	0.01%
May 15, 2024	ORBIMED ADVISORS LLC	new	-	28,100,400	28,100,400	0.52%
May 15, 2024	RA CAPITAL MANAGEMENT, L.P.	new	-	50,547,700	50,547,700	0.65%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	819,428	1,290,700	0.03%
May 15, 2024	Laurion Capital Management LP	new	-	13,729,500	13,729,500	0.12%
May 15, 2024	OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	added	55.89	1,622,810	2,119,160	0.15%
May 15, 2024	GOLDMAN SACHS GROUP INC	new	-	6,018,710	6,018,710	-%
May 15, 2024	FARALLON CAPITAL MANAGEMENT LLC	new	-	3,051,000	3,051,000	0.01%
May 15, 2024	KINGDON CAPITAL MANAGEMENT, L.L.C.	reduced	-49.52	5,909,610	21,357,000	2.33%

Are Funds Buying or Selling PRAX?

Are funds buying PRAX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PRAX

No. of Funds

Unveiling Praxis Precision Medicines Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	venrock healthcare capital partners iii, l.p.	8.9%	823,626	SC 13G/A
Feb 14, 2024	tri locum partners lp	2.8%	248,761	SC 13G/A
Feb 14, 2024	point72 asset management, l.p.	7.9%	692,252	SC 13G/A
Feb 14, 2024	cormorant asset management, lp	7.39%	633,345	SC 13G/A
Feb 14, 2024	verition fund management llc	8.0%	702,979	SC 13G
Feb 14, 2024	eventide asset management, llc	0.0%	0	SC 13G/A
Feb 14, 2024	pfm health sciences, lp	0.5%	6	SC 13G/A
Feb 13, 2024	avidity partners management lp	0%	0	SC 13G/A
Feb 13, 2024	huang james	0.0%	0	SC 13G/A
Feb 09, 2024	blackstone holdings i/ii gp l.l.c.	0.8%	70,273	SC 13G/A

Recent SEC filings of Praxis Precision Medicines Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Mar 29, 2024	424B5	Prospectus Filed
Mar 29, 2024	8-K	Current Report
Mar 27, 2024	424B5	Prospectus Filed
Mar 26, 2024	8-K	Current Report
Mar 12, 2024	EFFECT	EFFECT
Mar 08, 2024	CORRESP	CORRESP

Peers (Alternatives to Praxis Precision Medicines Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Praxis Precision Medicines Inc News

Latest updates

Praxis Precision Medicines Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q1	2020Q4	2020Q1	2019Q4
Revenue	-16.3%	431,000	515,000	468,000	781,000	683,000	576,833	470,667	364,500	258,333	152,167	46,000	87,000	128,000	-
Operating Expenses	49.4%	42,317,000	28,321,000	25,984,000	35,741,000	38,774,000	41,453,000	44,290,000	60,394,000	68,849,000	58,657,000	27,419,000	25,712,000	8,469,000	-
S&GA Expenses	-100.0%	-	9,933,000	8,724,000	10,127,000	13,270,000	13,124,000	13,851,000	16,774,000	16,197,000	15,146,000	9,490,000	9,440,000	1,601,000	-
R&D Expenses	46.7%	26,984,000	18,388,000	17,260,000	25,614,000	25,504,000	28,329,000	30,439,000	43,620,000	52,652,000	43,511,000	17,929,000	16,272,000	6,868,000	-
EBITDA Margin	-11.5%	-83.46	-74.87	-88.32	-107	-137	-191	-233	-271	-376	-615	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-5,000	-	-	-11,000	-
Earnings Before Taxes	-	-	-	-	-	-	-	-43,945,000	-	-	-58,587,000	-27,373,000	-25,706,000	-8,341,000	-
EBT Margin	-11.5%	-83.66	-75.04	-88.52	-107	-138	-191	-233	-272	-377	-616	-	-	-	-
Net Income	-47.3%	-39,600,000	-26,878,000	-24,632,000	-34,312,000	-37,455,000	-41,173,000	-43,945,000	-60,194,000	-68,717,000	-58,582,000	-27,373,000	-25,706,000	-8,330,000	-
Net Income Margin	-13.4%	-57.14	-50.38	-66.32	-92.18	-137	-223	-294	-378	-470	-616	-	-	-	-
Free Cashflow	12.6%	-20,907,000	-23,911,000	-23,215,000	-31,214,000	-32,846,000	-28,806,000	-44,964,000	-57,319,000	-54,398,000	-45,388,000	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	184.7%	250	88.00	107	133	98.00	115	137	180	240	293	324	354	279	303	120	48.00
Current Assets	149.5%	212	85.00	103	130	94.00	111	132	176	234	287	319	348	279	302	116	45.00
Cash Equivalents	87.4%	152	81.00	101	124	81.00	62.00	62.00	56.00	78.00	140	166	176	131	297	115	45.00
Net PPE	-19.0%	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00
Liabilities	13.4%	21.00	18.00	20.00	28.00	34.00	39.00	32.00	42.00	48.00	42.00	28.00	20.00	14.00	16.00	11.00	8.00
Current Liabilities	19.3%	19.00	16.00	17.00	24.00	30.00	34.00	29.00	39.00	45.00	38.00	25.00	16.00	14.00	16.00	10.00	7.00
Shareholder's Equity	229.7%	230	70.00	87.00	106	64.00	76.00	105	139	191	251	296	334	266	287	-	-
Retained Earnings	-6.1%	-693	-653	-627	-602	-568	-530	-489	-445	-385	-316	-258	-213	-176	-149	-123	-81.01
Additional Paid-In Capital	27.6%	923	724	714	708	633	607	595	585	577	568	554	547	443	437	-	-
Shares Outstanding	50.8%	13.00	9.00	129	129	58.00	-	46.00	45.00	45.00	45.00	42.00	40.00	-	-	-	-
Float	-	-	-	-	147	-	-	-	104	-	-	-	761	-	-	-	-

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	12.6%	-20,857	-23,861	-23,215	-31,214	-32,846	-28,806	-44,919	-57,209	-54,109	-44,857	-23,962	-30,013	-25,722	-20,228	-13,882	-9,944	-8,569	-	-
Share Based Compensation	152.8%	14,475	5,726	5,763	5,775	7,593	6,366	6,730	7,611	7,886	6,106	6,521	5,400	4,666	3,826	953	285	147	-	-
Cashflow From Investing	-182340.0%	-91,220	-50.00	-	5,000	34,000	22,594	47,955	34,890	-8,550	10,169	13,550	-24,229	-140,010	-	-	-	-	-	-
Cashflow From Financing	4329.4%	182,757	4,126	-	69,675	18,070	5,387	3,365	504	1,209	7,713	212	99,385	276	202,064	108,906	23,446	-30,000	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PRAX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Income Statement [Abstract]

Collaboration revenue

$ 431

$ 683

Operating expenses:

Research and development

26,984

25,504

General and administrative

15,333

13,270

Total operating expenses

42,317

38,774

Loss from operations

(41,886)

(38,091)

Other income:

Other income, net

2,333

636

Total other income

2,333

636

Net loss

$ (39,553)

$ (37,455)

Net loss per share attributable to common stockholders, basic (in dollars per share)

^[1]

$ (2.84)

$ (10.58)

Net loss per share attributable to common stockholders, diluted (in dollars per share)

^[1]

$ (2.84)

$ (10.58)

Weighted average common shares outstanding, basic (in shares)

^[1]

13,904,374

3,540,185

Weighted average common shares outstanding, diluted (in shares)

^[1]

13,904,374

3,540,185

[1]	Results have been retroactively adjusted to reflect the 1-for-15 reverse stock split effected on November 28, 2023. See Note 2 for details.

PRAX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 151,980	$ 81,300
Marketable securities	55,436	0
Prepaid expenses and other current assets	4,388	3,580
Total current assets	211,804	84,880
Long-term marketable securities	35,873	0
Property and equipment, net	476	588
Operating lease right-of-use assets	1,840	2,064
Other non-current assets	416	416
Total assets	250,409	87,948
Current liabilities:
Accounts payable	9,404	5,815
Accrued expenses	6,976	7,416
Operating lease liabilities	1,158	1,126
Current portion of deferred revenue	1,256	1,392
Total current liabilities	18,794	15,749
Long-term liabilities:
Non-current portion of operating lease liabilities	1,066	1,369
Non-current portion of deferred revenue	866	1,161
Total liabilities	20,726	18,279
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; 150,000,000 shares authorized; 13,258,047 shares issued and outstanding as of March 31, 2024, and 8,791,877 shares issued and outstanding as of December 31, 2023	13	13
Additional paid-in capital	923,141	723,577
Accumulated other comprehensive income	3	0
Accumulated deficit	(693,474)	(653,921)
Total stockholders’ equity	229,683	69,669
Total liabilities and stockholders’ equity	$ 250,409	$ 87,948

About Praxis Precision Medicines Inc

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.

CEO	Mr. Marcio Souza M.B.A.
WEBSITE	https://praxismedicines.com
INDUSTRY	Biotechnology
EMPLOYEES	109

Praxis Precision Medicines Inc Frequently Asked Questions

What is the ticker symbol for Praxis Precision Medicines Inc? What does PRAX stand for in stocks?

PRAX is the stock ticker symbol of Praxis Precision Medicines Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Praxis Precision Medicines Inc (PRAX)?

As of Thu May 16 2024, market cap of Praxis Precision Medicines Inc is 773.45 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PRAX stock?

You can check PRAX's fair value in chart for subscribers.

What is the fair value of PRAX stock?

You can check PRAX's fair value in chart for subscribers. The fair value of Praxis Precision Medicines Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Praxis Precision Medicines Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PRAX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Praxis Precision Medicines Inc a good stock to buy?

The fair value guage provides a quick view whether PRAX is over valued or under valued. Whether Praxis Precision Medicines Inc is cheap or expensive depends on the assumptions which impact Praxis Precision Medicines Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PRAX.

What is Praxis Precision Medicines Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, PRAX's PE ratio (Price to Earnings) is -6.17 and Price to Sales (PS) ratio is 352.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PRAX PE ratio will change depending on the future growth rate expectations of investors.